July 07, 2004
Torys has identified life sciences as a field of cross-border clover, and recently hired Cheryl Reicin, an American corporate and securities practitioner, as a partner in its Toronto office.
Cheryl was co-chair of her previous firm’s life sciences group, where she routinely assisted biotechs in bringing their drug products to market—a process that costs, on average, US$860 million.
The sector is busy in Canada. Canadian life sciences companies—and their investment bankers and venture capitalists—need U.S. investors and markets. Investment and marketing in both countries involves dealing with bodies such as the SEC, FDA, OSC and Health Canada. On its part, Canada offers U.S. life sciences companies 25 to 50 percent cost savings in R&D.